The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
Open accessAbstract
Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor‐2 (VEGFR 2) has been established as a therapeutic strategy for treating cancer. However, because of their low selectivity, most small molecule inhibitors of VEGFR 2 tyrosine kinase show unexpected adverse effects and limited anticancer efficacy. In the present study, we detailed the pharmacological properties of anlotinib, a highly potent and selective VEGFR 2 inhibitor, in preclinical models. Anlotinib occupied the ATP‐binding pocket of VEGFR 2 tyrosine kinase and showed high selectivity and inhibitory potency (IC50 <1 nmol/L) for VEGFR 2 relative to other tyrosine kinases. Concordant with this activity, anlotinib inhibited VEGF‐induced signaling and cell proliferation in HUVEC with picomolar IC50 values. However, micromolar concentrations of anlotinib were required to inhibit tumor cell proliferation directly in vitro. Anlotinib significantly inhibited HUVEC migration and tube formation; it also inhibited microvessel growth from explants of rat aorta in vitro and decreased vascular density in tumor tissue in vivo. Compared with the well‐known tyrosine kinase inhibitor sunitinib, once‐daily oral dose of anlotinib showed broader and stronger in vivo antitumor efficacy and, in some models, caused tumor regression in nude mice. Collectively, these results indicate that anlotinib is a well‐tolerated, orally active VEGFR 2 inhibitor that targets angiogenesis in tumor growth, and support ongoing clinical evaluation of anlotinib for a variety of malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Jaffe, E. A., Nachman, R. L., Becker, C. G., & Minick, C. R. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107470 · Cited by 6,856
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Neutralizing VEGF/ VEGFR2 interactions with monoclonal antibodies and blocking VEGFR kinase activity with small-molecule inhibitors are major approaches for targeting VEGF/VEGFR signaling in the treatment of solid tumors.(42,43) Several oral, non-specific VEGFR2 TKI have been approved for cancer therapy in the past 10…”
MethodVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., & Uchimaya, M. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9133-z · Cited by 2,045
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., Jeltsch, M., Jackson, D. G., Talikka, M., Rauvala, H., et al. (2004) · Nature Immunology · doi:10.1038/ni1013 · Cited by 1,421
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Shibuya, M. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs136 · Cited by 792
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Tian, S., Quan, H., Xie, C., Guo, H., Lü, F., Xu, Y., Li, J., & Lou, L. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01939.x · Cited by 513
Self-citationMolecular mechanisms of blood vessel formation
Bussolino, F., Mantovani, A., & Persico, G. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01074-8 · Cited by 470
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Sun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., Li, L., Wang, F., Hao, Y., Li, C., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0332-8 · Cited by 431
Signaling via Vascular Endothelial Growth Factor Receptors
Petrova, T. V., Makinen, T., & Alitalo, K. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4707 · Cited by 277
Mahooti, N. I., & Madri, J. A. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.24.3621 · Cited by 266
Takahashi, S. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1785 · Cited by 261
Clinical advances in the development of novel VEGFR2 inhibitors.
Fontanella, C., Ongaro, E., Bolzonello, S., Guardascione, M., Fasola, G., & Aprile, G. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.08.14 · Cited by 217
Antiangiogenic Therapy for Cancer: An Update
Al‐Husein, B., Abdalla, M., Trepte, M., DeRemer, D. L., & Somanath, P. R. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1147 · Cited by 216
Capsaicin Inhibits in Vitro and in Vivo Angiogenesis
Min, J.-K., Han, K.-Y., Kim, E.-C., Kim, Y.-M., Lee, S.-W., Kim, O.-H., Kim, K.-W., Gho, Y. S., & Kwon, Y.-G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3250 · Cited by 214
Bevacizumab: A Review of Its Use in Advanced Cancer
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 177
Onogawa, S., Kitadai, Y., Tanaka, S., Kuwai, T., Kimura, S., & Chayama, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03167.x · Cited by 151
BEEBE, J. S., Jani, J. P., Knauth, E. A., Goodwin, P., Higdon, C., Rossi, A. M., Emerson, E. O., Finkelstein, M. B., Floyd, E., Harriman, S. P., et al. (2003) · PubMed · Cited by 128
Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer
Sosman, J. A., Puzanov, I. J., & Atkins, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1975 · Cited by 120
The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis
Heinrich, E. L., Walser, T. C., Krysan, K., Liclican, E. L., Grant, J. L., Rodriguez, N., & Dubinett, S. M. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0089-0 · Cited by 99
Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications
Harper, J. W., & Moses, M. A. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7378-4_10 · Cited by 96
Martinelli, E., Troiani, T., Morgillo, F., Rodolico, G., Vitagliano, D., Morelli, M. P., Tuccillo, C., Vecchione, L., Capasso, A., Orditura, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0923 · Cited by 93
Tumor angiogenesis and anti-angiogenic therapies
Shahneh, F. Z., Baradaran, B., Zamani, F., & Maleki, L. A. (2013) · Human Antibodies · doi:10.3233/hab-130267 · Cited by 82
Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach
Sanphanya, K., Wattanapitayakul, S. K., Phowichit, S., Fokin, V. V., & Vajragupta, O. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.042 · Cited by 78
Antiangiogenesis therapy: an update after the first decade
Falco, S. D. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.1.1 · Cited by 72
Kerbel, R. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000134 · Cited by 72
Lee, C.-C., Liu, K.-J., Wu, Y.-C., Lin, S.-J., Chang, C.-C., & Huang, T. (2010) · Inflammation · doi:10.1007/s10753-010-9226-z · Cited by 70
Calycosin protects HUVECs from advanced glycation end products-induced macrophage infiltration
Xu, Y., Feng, L., Wang, S., Zhu, Q., Zheng, Z., Xiang, P., He, B., & Tang, D. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.05.041 · Cited by 66
Li, J., Zhou, N., Luo, K., Zhang, W., Li, X., Wu, C., & Bao, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915994 · Cited by 64
Marijon, H., Dokmak, S., Paradis, V., Zappa, M., Bièche, I., Bouattour, M., Raymond, É., & Faivre, S. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.011 · Cited by 52
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
Elice, F., & Rodeghiero, F. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70014-1 · Cited by 49
Han, J., Lee, K. H., Kim, S., Min, Y. J., Cho, E., Lee, Y., Lee, S.-H., Kim, H. Y., Lee, G. K., Nam, B., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.058 · Cited by 41
Mizumoto, A., Yamamoto, K., Nakayama, Y., Takara, K., Nakagawa, T., Hirano, T., & Hirai, M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226639 · Cited by 35
Yang, T.-H., Lee, C., Huang, W., & Lee, A. (2017) · Molecules · doi:10.3390/molecules22060913 · Cited by 34
Amino, N., Ideyama, Y., Yamano, M., Kuromitsu, S., Tajinda, K., Samizu, K., Hisamichi, H., Matsuhisa, A., Shirasuna, K., Kudoh, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2028 · Cited by 24
Onogawa, S., Kitadai, Y., Tanaka, S., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.026 · Cited by 16
Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
Cooper, M. R., Binkowski, C., Hartung, J., & Towle, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s80239 · Cited by 5
Cited by
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
Emerging therapies for small cell lung cancer
Yang, S., Zhang, Z., & Wang, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0736-3 · Cited by 407
Anlotinib: First Global Approval
Syed, Y. Y. (2018) · Drugs · doi:10.1007/s40265-018-0939-x · Cited by 268
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Liang, L., Hui, K., Hu, C., Wen, Y., Yang, S., Zhu, P., Wang, L., Xia, Y., Qiao, Y., Sun, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1093-3 · Cited by 187
Metadata
- Authors
- Xie, C., Wan, X., Quan, H., Zheng, M., Fu, L., Li, Y., & Lou, L.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2018-03-25
- Volume
- 109
- Issue
- 4
- Pages
- 1207-1219
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2791667474
- Cited by
- 348
- References
- 49
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.